Presentations by Program

Global Surveillance of the Activity of Sulbactam combined with the Novel β-lactamase Inhibitor ETX2514 against Clinical Isolates of Acinetobacter baumannii from 2014

Kenneth Lawrence, ID Week 2016

Human PK and Dose Projection of ETX2514 / Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii

John O’Donnell, ID Week 2016

Sulbactam Combined with the Novel β–lactamase Inhibitor ETX2514 for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections

Alita Miller, ID Week 2016

Addressing the Evolving Challenge of β-lactamase Mediated Antimicrobial Resistance: ETX2514, a Next-generation BLI with Potent, Broad Spectrum Activity Against Class A, C & D Enzymes

Ruben Tommasi, ASM Microbe 2016

In Vitro and In Vivo Efficacy of the Novel β-lactamase Inhibitor ETX2514 Combined with Sulbactam Against Multidrug Resistant Acinetobacter baumannii

John O’Donnell, ASM Microbe 2016

ETX2514, a Novel, Rationally Designed Inhibitor of Class A, C and D β–lactamases, for the Treatment of Gram-negative Infections

Adam Shapiro, ASM Microbe 2016

← Previous
1
2
3
4
5
6 (current)
Next →